HOME    NEWS    SPECIAL REPORT    PHOTO    COMMENTARY    VOICE
NEWS > Technology
1st China-made AIDS drug approved for human tests
2005-12-02 00:54:09 Xinhua English

BEIJING, Dec. 2(Xinhuanet)-- The Academy of Military Medical Science has announced that it is producing China's first AIDS drug with independent intellectual property rights and that it has been approved for clinical trials.

He Fuchu, the academy's vice president said that IBE-5 marks a major breakthrough and has outperformed combination therapies in tests on monkeys.

He said that the drug has now been approved by the State Food and Drug Administration for clinical trials involving humans.

"The safety of the new drug is reliable," he said, adding that it showed remarkable performance in curbing the duplication of HIV and was effective for longer than combination therapies.

The academy began to develop IBE-5 in 1994 and applied for a national patent for it in 1996.

The Jiangzhong Pharmaceutical Group, a major domestic medicine producer, joined the program in 1996, said Zhong Hongguang, the group's board chairman.

He added that Jiangzhong has applied for patent protection for the drug and its production. Enditem

MORE NEWS
Likely cause of space shuttle trouble found: NASA  
Archaeologists find site of grand gate of 1,300-year-old palace  
Stem cell transplantation safer in HK  
China studies new treatments for human cases of bird flu  
Traditional Chinese medicine applied in space flights  
Intel teams up with partners on multimedia platform  
Britain to invest more in stem cell research  
China to require all mobile phone users to register  

SINA English is the English-language destination for news and information about China. Find general information on life, culture and travel in China through our news and special reports£¬or find business partners through our online Business Directory. For investment opportunities with SINA, please click the link "Investor" below.
| About SINA | Investor | Media Kit | Comments or Question? |
Copyright© 2005 SINA.com. All Rights Reserved